(4R,6R)-6-{2-[(1S,2S,6S,8S,8aR)-1,2,6,7,8.8a-Hexahydro-6-t-butyldimethylsilyloxy-8-(2,2-dimethyl-4-pentenoyloxy)-2-methyl-1-naphthyl]ethyl}tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one | 159224-72-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (4R,6R)-6-{2-[(1S,2S,6S,8S,8aR)-1,2,6,7,8.8a-Hexahydro-6-t-butyldimethylsilyloxy-8-(2,2-dimethyl-4-pentenoyloxy)-2-methyl-1-naphthyl]ethyl}tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one
• 英文别名: (4R,6R)-6-{2-[(1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-6-t-butyldimethylsilyloxy-8-(2,2-dimethyl-4-pentenoyloxy)-2-methyl-1-naphthyl]ethyl}tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one；[(1S,3S,7S,8S,8aR)-3-[tert-butyl(dimethyl)silyl]oxy-8-[2-[(2R,4R)-4-[tert-butyl(dimethyl)silyl]oxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylpent-4-enoate
• CAS: 159224-72-3
• 化学式: C₃₇H₆₄O₆Si₂
• 分子量: 661.083
• InChiKey: SLMUNECZRUNTQG-OMXYSMRYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.54
• 重原子数：
  45
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (4R,6R)-6-{2[(1S,2S,6S,8S,8AR)-1,2,6,7,8,8a-hexahydro-6-t-butyldimethylsilyloxy-8-hydroxy-2-methyl-1-naphthyl]ethyl}-tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one 、 2,2-二甲基-4-戊烯酸 生成 (4R,6R)-6-{2-[(1S,2S,6S,8S,8aR)-1,2,6,7,8.8a-Hexahydro-6-t-butyldimethylsilyloxy-8-(2,2-dimethyl-4-pentenoyloxy)-2-methyl-1-naphthyl]ethyl}tetrahydro-4-t-butyldimethylsilyloxy-2H-pyran-2-one
  参考文献：
  名称：

  Hexahydronaphthalene ester derivatives, their preparation and their

  摘要：

  化合物的化学式（I）：##STR1## [其中R.sup.1代表化学式（II）或（III）的基团：##STR2## R.sup.2是烷基，烯基或炔基；R.sup.3和R.sup.4分别是氢，烷基，烯基或炔基；R.sup.5是氢或羧基保护基团；R.sup.a是氢或化学式和--OR.sup.6的基团；R.sup.6，R.sup.6a和R.sup.6b分别是氢，羟基保护基团，烷基，烷烷基磺酰基，卤代烷烷基磺酰基或芳基磺酰基]及其盐和酯具有抑制胆固醇合成的能力，因此可用于治疗和预防高胆固醇血症和各种心脏疾病。

  公开号：

  US05451688A1

文献信息

• Hexahydronaphthalene ester derivatives their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05827855A1

  公开（公告）日：1998-10-27

  Compounds of formula (I): ##STR1## wherein R.sup.1 represents a group of formula (II) or (III): ##STR2## R.sup.2 is alkyl, alkenyl or alkynyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, alkenyl or alkynyl; R.sup.5 is hydrogen or a carboxy-protecting group; R.sup.a is a group of formula --OR.sup.6 ; R.sup.6 is hydrogen; R.sup.6a and R.sup.6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulfonyl, halogenated alkanesulfonyl or arysulfonyl, and their salts and esters. Such compounds inhibit the synthesis of cholesterol, and can be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.

  化合物的式子（I）：##STR1## 其中R.sup.1代表式子（II）或（III）的基团：##STR2## R.sup.2是烷基，烯基或炔基；R.sup.3和R.sup.4分别是氢，烷基，烯基或炔基；R.sup.5是氢或羧基保护基团；R.sup.a是式子--OR.sup.6的基团；R.sup.6是氢；R.sup.6a和R.sup.6b分别是氢，羟基保护基团，烷基，烷基磺酰，卤代烷基磺酰或芳基磺酰，以及它们的盐和酯。这些化合物抑制胆固醇的合成，可用于治疗和预防高胆固醇血症和各种心脏疾病。
• Hexahydronaphthalene ester derivatives, their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05451688A1

  公开（公告）日：1995-09-19

  Compounds of formula (I): ##STR1## [wherein R.sup.1 represents a group of formula (II) or (III): ##STR2## R.sup.2 is alkyl, alkenyl or alkynyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, alkenyl or alkynyl; R.sup.5 is hydrogen or a carboxy-protecting group; R.sup.a is hydrogen or a group of formula and --OR.sup.6 ; R.sup.6, R.sup.6a and R.sup.6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulfonyl, halogenated alkanesulfonyl or arylsulfonyl] and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.

  化合物的化学式（I）：##STR1## [其中R.sup.1代表化学式（II）或（III）的基团：##STR2## R.sup.2是烷基，烯基或炔基；R.sup.3和R.sup.4分别是氢，烷基，烯基或炔基；R.sup.5是氢或羧基保护基团；R.sup.a是氢或化学式和--OR.sup.6的基团；R.sup.6，R.sup.6a和R.sup.6b分别是氢，羟基保护基团，烷基，烷烷基磺酰基，卤代烷烷基磺酰基或芳基磺酰基]及其盐和酯具有抑制胆固醇合成的能力，因此可用于治疗和预防高胆固醇血症和各种心脏疾病。